{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:45:25Z","timestamp":1785386725672,"version":"3.55.0"},"reference-count":34,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:p>Immune checkpoint inhibitor (ICI) therapies are now first-line therapy for many advanced malignancies in adults, with emerging use in children. With increasing ICI use, prompt recognition and optimal management of ICI-associated immune-related adverse events (IRAEs) are critical. Nearly 60% of ICI-treated adults develop IRAEs, which commonly manifest as autoimmune skin, gastrointestinal, and endocrine disease and can be life-threatening. The incidence, presentation, and disease course of spontaneous autoimmune diseases differ between adults and children, but the pattern of pediatric IRAEs is currently unclear. We report a case of a pediatric patient presenting with new onset autoimmune diabetes mellitus and diabetic ketoacidosis during ICI treatment of fibrolamellar hepatocellular carcinoma (FLC). Distinct from spontaneous type 1 diabetes mellitus (T1DM), this patient progressed rapidly and was negative for known \u03b2 cell autoantibodies. Additionally, the patient was positive for 21-hydroxylase autoantibodies, suggesting development of concomitant adrenal autoimmunity. Current guidelines for the management of IRAEs in adults may not be appropriate for the management of pediatric patients, who may have different autoimmune risks in a developmental context.<\/jats:p>","DOI":"10.1542\/peds.2021-053363","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T08:05:47Z","timestamp":1646985947000},"source":"Crossref","is-referenced-by-count":6,"title":["Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon \u03b1"],"prefix":"10.1542","volume":"149","author":[{"given":"Aditi","family":"Dasgupta","sequence":"first","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tsay","sequence":"additional","affiliation":[{"name":"Divisions of Pediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Federman","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa G.","family":"Lechner","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes, and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen A.","family":"Su","sequence":"additional","affiliation":[{"name":"Divisions of Pediatric Endocrinology"},{"name":"Department of Microbiology, Immunology, and Molecular Genetics, UCLA Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"issue":"11","key":"2022040102591642500_B1","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"2022040102591642500_B2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1297\/cpe.28.59","article-title":"Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events","volume":"28","author":"Ihara","year":"2019","journal-title":"Clin Pediatr Endocrinol"},{"issue":"2","key":"2022040102591642500_B3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"issue":"3","key":"2022040102591642500_B4","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2022040102591642500_B5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.31486\/toj.18.0055","article-title":"Immune checkpoint inhibitors in pediatric solid tumors: status in 2018","volume":"18","author":"Kabir","year":"2018","journal-title":"Ochsner J"},{"key":"2022040102591642500_B6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2017.05.006","article-title":"Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies","volume":"58","author":"Park","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2022040102591642500_B7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev-cancerbio-030419-033436","article-title":"Immune-based approaches for the treatment of pediatric malignancies","volume":"4","author":"Bosse","year":"2020","journal-title":"Annu Rev Cancer Biol"},{"issue":"4","key":"2022040102591642500_B8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2022040102591642500_B9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fphar.2019.01300","article-title":"Antitumor activity and treatment-related toxicity associated with nivolumab Plus ipilimumab in advanced malignancies: a systematic review and meta-analysis","volume":"10","author":"Xu","year":"2019","journal-title":"Front Pharmacol"},{"issue":"6","key":"2022040102591642500_B10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2352-4642(20)30135-8","article-title":"The immune system of children: the key to understanding SARS-CoV-2 susceptibility?","volume":"4","author":"Carsetti","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"issue":"1821","key":"2022040102591642500_B11","first-page":"20143085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc Biol Sci"},{"issue":"1","key":"2022040102591642500_B12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12916-017-0958-6","article-title":"Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study","volume":"15","author":"Rogers","year":"2017","journal-title":"BMC Med"},{"issue":"5","key":"2022040102591642500_B13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000513358","article-title":"Early experiences with triple immunochemotherapy in adolescents and young adults with high-risk fibrolamellar carcinoma","volume":"99","author":"Gottlieb","year":"2021","journal-title":"Oncology"},{"issue":"3","key":"2022040102591642500_B14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4314\/ahs.v14i3.5","article-title":"Glycosylated haemoglobin is markedly elevated in new and known diabetes patients with hyperglycaemic ketoacidosis","volume":"14","author":"O Ekpebegh","year":"2014","journal-title":"Afr Health Sci"},{"issue":"1","key":"2022040102591642500_B15","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"2022040102591642500_B16","first-page":"705","article-title":"[21-hydroxylase autoantibodies as a marker of adrenal involvement in patients with autoimmune endocrinopathies]","volume":"57","author":"Degros","year":"1999","journal-title":"Ann Biol Clin (Paris)"},{"issue":"3","key":"2022040102591642500_B17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2022040102591642500_B18","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"12","key":"2022040102591642500_B19","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"2022040102591642500_B20","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc20-0740","article-title":"Anti-PD-1 therapy-sssociated Type 1 diabetes in a pediatric patient with relapsed classical Hodgkin lymphoma","volume":"43","author":"Samoa","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"2022040102591642500_B21","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc10-2274","article-title":"Type 1 diabetes and interferon therapy: a nationwide survey in Japan","volume":"34","author":"Nakamura","year":"2011","journal-title":"Diabetes Care"},{"key":"2022040102591642500_B22","article-title":"Phase Ib\/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma [published online ahead of print October 25, 2018]","author":"Davar","journal-title":"J Clin Oncol"},{"issue":"8","key":"2022040102591642500_B23","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1158\/1078-0432.CCR-17-3436","article-title":"Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 study","volume":"24","author":"Atkins","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2022040102591642500_B24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"2022040102591642500_B25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc"},{"issue":"6","key":"2022040102591642500_B26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc"},{"key":"2022040102591642500_B27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison\u2019s disease: A rare, persistent and potentially lethal side-effect","volume":"97","author":"Hescot","year":"2018","journal-title":"Eur J Cancer"},{"key":"2022040102591642500_B28","unstructured":"National Comprehensive Cancer Network\n          . Management of immunotherapy-related toxicities (Version 3.2021). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Accessed June 1, 2021"},{"issue":"18","key":"2022040102591642500_B29","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"7","key":"2022040102591642500_B30","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"28","key":"2022040102591642500_B31","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.18632\/oncotarget.27665","article-title":"Rapid onset type 1 diabetes with anti-PD-1 directed therapy","volume":"11","author":"Yun","year":"2020","journal-title":"Oncotarget"},{"issue":"5","key":"2022040102591642500_B32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.2019-0674","article-title":"Anti-PD1-induced immune-related adverse events and survival outcomes in advanced melanoma","volume":"25","author":"Suo","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"2022040102591642500_B33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"2022040102591642500_B34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-053363\/1275585\/peds_2021053363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-053363\/1275585\/peds_2021053363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T03:01:44Z","timestamp":1648782104000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/149\/4\/e2021053363\/185397\/Polyendocrine-Autoimmunity-and-Diabetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,11]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2021-053363","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"article-number":"e2021053363"}}